804-P: A1C and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Kidney Function

Introduction and Objective: This post hoc analysis assessed treatment outcomes of IcoSema (a once-weekly combination of basal insulin icodec [icodec] and semaglutide) vs icodec (COMBINE 1), semaglutide 1.0 mg (COMBINE 2), and daily basal-bolus therapy (insulin glargine U100 + insulin aspart) (COMBINE 3) in adults with T2D by kidney function subgroups. Methods: Treatment outcomes were assessed by kidney function subgroup at baseline (eGFR ≥90; 60-<90; 30-<60; <30; all mL/min/1.73m2) by trial. Results: For IcoSema vs comparators, there were no meaningful interactions between treatment and kidney function subgroup for A1C reduction (baseline to week 52; Fig), rates of combined clinically significant or severe hypoglycemia (only assessed for COMBINE 1 and 3), and achievement of A1C <7% at week 52 without weight gain and without combined clinically significant or severe hypoglycemia. Estimated treatment differences/ratios for these outcomes were generally consistent, with no clear trend across kidney function subgroups. Conclusion: For IcoSema vs comparators, A1C reductions, combined clinically significant or severe hypoglycemia rates, and achievement of A1C <7% without weight gain and combined clinically significant or severe hypoglycemia were generally consistent across kidney function subgroups. Disclosure L. Ji: None. M. Benamar: Employee; Novo Nordisk A/S. B. Harvey: Employee; Novo Nordisk A/S. A. Navarria: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. P. Ponzani: Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk, Novartis AG, Bayer Pharmaceuticals, Inc, AstraZeneca. Speaker's Bureau; Menarini. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. A. Unnikrishnan: Speaker's Bureau; Eli Lilly and Company, Mankind Pharma Ltd, Novo Nordisk, Sanofi. R.R. Rea: None. Funding Novo Nordisk A/S